Filing Details

Accession Number:
0001181431-12-054534
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-10-11 19:52:16
Reporting Period:
2012-10-10
Filing Date:
2012-10-11
Accepted Time:
2012-10-11 19:52:16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1505512 Regulus Therapeutics Inc. RGLS Pharmaceutical Preparations (2834) 264738379
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
897667 T Stanley Crooke C/O Regulus Therapeutics Inc.
3545 John Hopkins Court, Suite 210
San Diego CA 92121
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-10-10 6,299,500 $0.00 6,299,500 No 4 C Indirect See footnote
Common Stock Acquisiton 2012-10-10 750,000 $4.00 7,049,500 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See footnote
No 4 P Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2012-10-10 6,299,500 $0.00 6,299,500 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
Footnotes
  1. Upon the closing of the Issuer's initial public offering, every 2 shares of Series A Preferred Stock automatically converted into 1 share of Common Stock and had no expiration date.
  2. The shares are held by Isis Pharmaceuticals, Inc ("Isis"). The Reporting Person is an executive officer and director of Isis. The Reporting Person may be deemed to beneficially own the shares. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein.
  3. The shares were purchased at the Issuer's initial public offering.